FrancophonIA/ELRC3.0 huggingface dataset:
English: In the study 40.4% and 51.7% patients in the of nebulised beclometasone dipropionate and budesonide groups respectively did not experience any major exacerbation (primary endpoint).
Estonian: Uuringus ei tekkinud olulisi ägenemisi (esmane tulemusnäitaja) vastavalt 40,4%-l ja 51,7%-l CLENIL'i ja budesoniidi rühma patsientidest.
English: Do not inject into a vein or use orally.
Estonian: Ärge süstige seda veeni ega kasutage suu kaudu.
English: In addition, the time to first exacerbation was longer in children treated with nebulised beclometasone dipropionate.
Estonian: Peale selle oli CLENIL'iga ravitud lastel esimese ägenemiseni kulunud aeg pikem.
English: • cough
Estonian: *Harv
English: Bend the ampoule backwards and forwards (Figure A).
Estonian: Painutada ampulliriba ette-taha (joonis A).
English: Read the package leaflet before use.
Estonian: Enne kasutamist hoolikalt loksutada.
English: • If you have an infection of nasal and paranasal cavities you have to be treated with suitable therapies,
Estonian: • Kui teil on nina ja ninakõrvalurgete infektsioon, tuleb neid sobival viisil ravida, kuid need ei ole konkreetsed vastunäidustused CLENIL'i kasutamisele.
English: If only half dose of {INVENTED NAME} 800 micrograms is needed, hold the ampoule upside down, ensuring that the graduation mark is clearly visible and apply moderate pressure.
Estonian: Kui vajatakse ainult CLENIL 800 mikrogrammi poolt annust, hoidke ampulli alaspidi, nii et graduatsioonitähis on selgelt näha ja vajutage mõõdukalt.
English: The affinity of beclometasone dipropionate and its main active metabolite, beclometasone monopropionate (B17MP), for the human glucocorticoid receptor has been determined.
Estonian: Beklometasoondipropionaadil ja selle põhilisel aktiivsel metaboliidil beklometasoonmonopropionaadil (B17MP) on tõestatud afiinsus inimese glükokortikoidi retseptori suhtes.
English: In addition, the duration of treatment of recurrent wheezing should not exceed 3 months, unless diagnosis of asthma is likely to avoid an unnecessary longterm exposure (see section 4.4).
Estonian: Et vältida ebavajalikku pikaajalist ravi, ei tohi korduvate vilistava hingamisepisoodide ravi kestus ületada 3 kuud, välja arvatud juhul, kui on diagnoositud astma (vt lõik
English: For 800 micrograms ampoule: after the first opening of the ampoule, store it in a refrigerator (2-8°C).
Estonian: 800 mikrogrammi ampull: Pärast esmakordset avamist: Hoida külmkapis (2 °C...8 °C).
English: Adrenal suppression**
Estonian: Adrenaalne supressioon
English: Very common side effects (may affect more than 1 in 10 people):
Estonian: Väga sageli esinevad kõrvaltoimed (võivad esineda rohkem kui 1 inimesel 10st):
English: There is an approximately linear increase in systemic exposure of the active metabolite B17MP with increasing inhaled dose.
Estonian: Aktiivse metaboliidi B17MP süsteemne ekspositsioon suureneb inhaleeritava annuse suurenedes peaaegu lineaarselt.
English: The ampoule closed in this way must be stored at 2-8◦C (in the refrigerator) and the remaining quantity has to be used within 12
Estonian: Selliselt suletud ampulli peab hoidma temperatuuril 2 ◦C kuni 8 ◦C (külmkapis) ja ülejäänud kogus tuleb ära kasutada 12 tunni jooksul pärast esmakordset avamist.
English: Nevertheless, as precautionary measure when high doses of beclometasone dipropionate are inhaled you should avoid breast-feeding for 4 h after administration.
Estonian: Inhaleeritava beklometasoondipropionaadi kasutamisel suurtes annustes tuleb siiski ettevaatusena vältida imetamist 4 tunni jooksul pärast manustamist.
English: Driving and using machines {INVENTED NAME} is unlikely to affect your ability to drive and use machines.
Estonian: CLENIL tõenäoliselt ei mõjuta teie autojuhtimise ja masinate käsitsemise võimet.
English: What {INVENTED NAME} looks like and contents of the pack {INVENTED NAME} is a white or almost white nebuliser suspension.
Estonian: CLENIL on valge või peaaegu valge nebuliseeritav suspensioon.
English: How to store {INVENTED NAME} 6.
Estonian: Kuidas CLENIL'i säilitada 6.
English: Corticosteroids pass into breast milk at low amounts.
Estonian: Glükokortikoide imendub rinnapiima vähesel hulgal.
English: Rare side effects (may affect up to 1 in 1000people):
Estonian: Harva esinevad kõrvaltoimed (võivad esineda kuni 1 inimesel 1000st):
English: {INVENTED NAME} should not be injected or administered orally.
Estonian: CLENIL'i ei tohi süstida ega manustada suukaudselt.
English: Beclometasone was teratogenic and embryolethal in animals after, subcutaneous and oral administration.
Estonian: Beklometasoon oli loomadele pärast subkutaanset ja suukaudset manustamist teratogeenne ja embrüoletaalne.
English: Nebulised beclometasone dipropionate was evaluated in 276 children aged 1-4 years with frequent wheezing in a randomized, double-blind, 12-week controlled trial.
Estonian: CLENIL'i kasutamist hinnati randomiseeritud, topeltpimedas, 12-nädalases kontrollrühmaga uuringus 276 lapsel vanuses 1…4 aastat, kellel esines sageli vilistavat hingamist.
English: Adverse reactions observed in clinical trials with inhaled beclometasone in the treatment of asthma and wheezing are listed in the table below according the MedDRA system organ class and frequencies: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to ≤1/100); rare (≥1/10,000 to ≤1/1,000); very rare (≤1/10,000), not known (cannot be estimated from the available data).
Estonian: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000
English: Then contact your doctor straightaway.
Estonian: Seejärel võtke kohe ühendust oma arstiga.
English: 5 ampoules containing 1 ml suspension each
Estonian: RAVIMVORM JA PAKENDI SUURUS Nebuliseeritav suspensioon 5 ampulli, igas 1 ml suspensiooni
English: Once the nebuliser bowl cap is inserted, the nebuliser should be shaken gently to mix the content.
Estonian: Nebulisaatorit tuleb sisu segunemiseks ettevaatlikult loksutada.
English: Follow the manufacturer's instructions for cleaning your nebuliser.
Estonian: Puhastamine: Nebulisaatori puhastamisel järgige tootja juhiseid.
English: These effects are much less likely to occur than with oral corticosteroids.
Estonian: Suukaudsete kortikosteroidide kasutamisel on nende tekkimine vähem tõenäoline.
English: No significant effect on morning serum cortisol levels was reported in asthmatic patients after a 3-week treatment period of 1600 and 3200 µg per day b.i.d.
Estonian: Kolmenädalane raviperiood 1600 ja 3200 µg üks kord ööpäevas manustamisel nebulisaatori kaudu ei mõjutanud oluliselt astmaga patsientidel hommikusi seerumi kortisoolitasemeid.
English: • nausea (feeling sick) and stomach pains.
Estonian: • iiveldus ja kõhuvalud;
English: LIST OF EXCIPIENTS Excipients: polysorbate 20, sorbitan laurate, sodium chloride, water for injections
Estonian: ABIAINED Abiained: polüsorbaat 20, sorbitaanlauraat, naatriumkloriid, süstevesi
English: {INVENTED NAME} contains the active substance beclometasone dipropionate.
Estonian: CLENIL sisaldab toimeainena beklometasoondipropionaati.
English: If you forget to use {INVENTED NAME}:
Estonian: Kui te unustate CLENIL'i kasutada
English: 800-1,600 micrograms twice daily (total daily dose: 1600 - 3200 micrograms)
Estonian: 800...1600 mikrogrammi kaks korda ööpäevas (koguannus ööpäevas:
English: In case of asthma disease, {INVENTED NAME} must be used regularly on a daily basis.
Estonian: CLENIL'i tuleb kasutada regulaarselt iga päev.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION {INVENTED NAME} 400 mcg
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) CLENIL 400 mikrogrammi
English: Tremor
Estonian: Düspnoe
English: If only half dose of {INVENTED NAME} 800 micrograms is needed, reinsert the cap upside down by pushing it onto the vial.
Estonian: Kui vajatakse ainult Clenil 800 mikrogrammi poolt annust, tuleb sisestada kork uuesti alaspidi, lükates selle ampullile.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION {INVENTED NAME} 800 mcg
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) CLENIL 800 mikrogrammi
English: Comparable efficacy in controlling asthma was demonstrated by the two treatments at study end in terms of pulmonary function tests, asthma exacerbations, symptoms and the use of rescue salbutamol (Terzano et al., 2003).
Estonian: Uuringu lõpus näidati kopsufunktsiooni testide, astma ägenemiste, sümptomite ja leevendava ravimina salbutamooli kasutamise põhjal nende kahe raviviisi võrreldavat efektiivsust astma kontrolli all hoidmisel.
English: {INVENTED NAME} can be diluted.
Estonian: CLENIL'i võib lahjendada.
English: It must be recommended that patients rinse their mouth with water immediately after inhalation to reduce the frequency of oral candidiasis.
Estonian: Suu kandidiaasi esinemissageduse vähendamiseks tuleb patsientidel soovitada kohe pärast inhalatsiooni veega suud loputada.
English: Batch:
Estonian: SN:
English: The active substance is beclometasone dipropionate.
Estonian: Toimeaine on beklometasoondipropionaat.
English: CLENIL and associated names (see Annex I) 400 micrograms nebuliser suspension CLENIL and associated names (see Annex I) 800 micrograms nebuliser suspension
Estonian: PAKENDI INFOLEHT: TEAVE KASUTAJALE CLENIL 400 mikrogrammi nebuliseeritav suspensioon CLENIL 800 mikrogrammi nebuliseeritav suspensioon Beklometasoondipropionaat
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each 2 ml ampoule contains 800 micrograms beclometasone dipropionate.
Estonian: TOIMEAINE(TE) SISALDUS Iga 2 ml ampull sisaldab 800 mikrogrammi beklometasoondipropionaati.
English: Each 2 ml ampoule contains 800 micrograms beclometasone dipropionate.
Estonian: Iga 2 ml ampull sisaldab 800 mikrogrammi beklometasoondipropionaati.
English: You can used {INVENTED NAME} 800 micrograms ampoule to get 400 micrograms (half the content) using the graduation mark as described below.
Estonian: CLENIL 800 mikrogrammi kasutamisel tuleb kasutada poole annuse mõõtmiseks ampullil olevat gradueerimistähist (mis vastab 400 mikrogrammile).
English: Sorbitan laurate Sodium chloride Water for injections
Estonian: Polüsorbaat 20 Sorbitaanlauraat Naatriumkloriid Süstevesi
English: What you need to know before you use {INVENTED NAME} 3.
Estonian: 1. Mis ravim on CLENIL ja milleks seda kasutatakse 2. Mida on vaja teada enne CLENIL'i kasutamist 3.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each 1 ml ampoule contains 400 micrograms beclometasone dipropionate.
Estonian: TOIMEAINE(TE) SISALDUS Iga 1 ml ampull sisaldab 400 mikrogrammi beklometasoondipropionaati.
English: 400-800 micrograms twice daily (total daily dose: 800 - 1600 micrograms)
Estonian: • 400...800 mikrogrammi kaks korda ööpäevas, mis vastab ööpäevasele koguannusele 800...1600 mikrogrammi.
English: Each 1 ml ampoule contains 400 micrograms beclometasone dipropionate.
Estonian: Iga 1 ml ampull sisaldab 400 mikrogrammi beklometasoondipropionaati.
English: Wheezing
Estonian: Köha
English: Annex III Product information
Estonian: III LISA RAVIMIINFO OLULISTE OSADE MUUDATUSED
English: This product information is the outcome of the referral procedure to which this Commission decision relates.
Estonian: Need ravimi omaduste kokkuvõtte ja pakendi infolehe oluliste osade muudatused tulenevad esildismenetlusest.
English: Common side effects (may affect up to 1 in 10 people):
Estonian: Sageli esinevad kõrvaltoimed (võivad esineda kuni 1 inimesel 10st):
English: {INVENTED NAME}{INVENTED NAME}If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Estonian: Kui teil on lisaküsimusi selle ravimi kasutamise kohta, pidage nõu oma arsti või apteekriga.
English: B end the amp oule back ward s and forwards (Figure A).
Estonian: Painutada ampullide riba ette-taha (joonis A).
English: PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING POUCH
Estonian: VAHEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED KOTIKE
English: If you develop an immediate increase in wheezing, shortness of breath and cough after using {INVENTED NAME}, you should discontinued immediately {INVENTED NAME} and you should contact your doctor.
Estonian: • Kui pärast CLENIL'i kasutamist tugevneb kohe vilistav hingamine, õhupuudus ja köha, peate
English: Use the ampoules within 3 months from the first opening the pouch.
Estonian: Pärast kotikese esmakordset avamist kasutada ampullid ära 3 kuu jooksul.
English: Each polyethylene ampoule contains 400 micrograms beclometasone dipropionate suspension in 1 ml.
Estonian: Iga 1 ml ampull sisaldab 400 mikrogrammi veevaba beklometasoondipropionaati.
English: Exp: Use the ampoules within 3 months from the first opening the pouch.
Estonian: KÕLBLIKKUSAEG Kõlblik kuni: Pärast kotikese esmakordset avamist kasutada ampullid ära 3 kuu jooksul.
English: Each polyethylene ampoule contains 800 micrograms beclometasone dipropionate suspension in 2 ml.
Estonian: Iga 2 ml ampull sisaldab 800 mikrogrammi veevaba beklometasoondipropionaati.
English: {INVENTED NAME} 800 micrograms
Estonian: 800...1600 mikrogrammi)
English: {INVENTED NAME} 400 micrograms
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) CLENIL 400 mikrogrammi
English: Your doctor will try to prevent these effects by prescribing {INVENTED NAME} in the lowest effective dose.
Estonian: Teie arst püüab määrata teile nende toimete ennetamiseks CLENIL'i võimalikult väikese annuse, mis teil astmat kontrolli all hoiab.
English: What measures are being taken to ensure the safe and effective use of Blitzima?
Estonian: Mis meetmed võetakse, et tagada Blitzima ohutu ja efektiivne kasutamine?
English: The full EPAR for Blitzima can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Blitzima kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Blitzima
Estonian: Muu teave Blitzima kohta
English: This means that Blitzima is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Estonian: See tähendab, et Blitzima sarnaneb bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba.
English: What is Blitzima and what is it used for?
Estonian: Mis on Blitzima ja milleks seda kasutatakse?
English: In this study improvement was seen in 96% of cases (67 of 70 patients) with Blitzima and 90% (63 of 70 patients) with Rituxan.
Estonian: Selles uuringus oli ravivastusega patsiente 96% Blitzimat kasutanutest (67 patsienti 70st) ja 90% Rituxani kasutanutest (63 patsienti 70st).
English: Why is Blitzima approved?
Estonian: Miks Blitzima heaks kiideti?
English: This is a summary of the European public assessment report (EPAR) for Blitzima.
Estonian: See on ravimi Blitzima Euroopa avaliku hindamisaruande kokkuvõte.
English: Further evidence came from supportive studies, including one involving 121 patients with advanced follicular lymphoma, where adding Blitzima to chemotherapy medicines was at least as effective as adding Rituxan, the US version of MabThera.
Estonian: Täiendav tõendusmaterjal pärines toetavatest uuringutest, sealhulgas uuringust, milles osales 121 kaugelearenenud follikulaarse lümfoomiga patsienti ning kus Blitzima lisamine keemiaravile osutus vähemalt sama efektiivseks kui Rituxani (MabThera USA analoog) lisamine keemiaravile.
English: Patients are also to receive an alert card to carry at all times, instructing them to contact their doctor immediately if they have any of the listed symptoms of infection.
Estonian: Patsientidele antakse ka hoiatuskaart, mida nad peavad kogu aeg kaasas kandma ja milles neil soovitatakse nimetatud infektsioonisümptomite ilmnemisel otsekohe arsti poole pöörduda.
English: It is not intended to provide practical advice on how to use Blitzima.
Estonian: Hindamisaruandes ei anta Blitzima kasutamise praktilisi nõuandeid.
English: Blitzima is a medicine used in adults to treat the following blood cancers and inflammatory conditions:
Estonian: Blitzima on ravim, mida kasutatakse järgmiste verevähkide ja põletikuhaiguste raviks täiskasvanutel:
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Blitzima have also been included in the summary of product characteristics and the package leaflet.
Estonian: Blitzima ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Blitzima has a highly similar structure, purity and biological activity to MabThera and is distributed in the body in the same way.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on Blitzima struktuuri, puhtuse ja bioloogilise toime poolest väga sarnane MabTheraga ning Blitzima jaotub organismis samamoodi.
English: What are the risks associated with Blitzima?
Estonian: Mis riskid Blitzimaga kaasnevad?
English: Therefore, the Agency's view was that, as for MabThera, the benefit outweighs the identified risk and it recommended that Blitzima be given marketing authorisation.
Estonian: Seetõttu arvas Euroopa Ravimiamet, et nagu ka MabThera korral, ületab Blitzima kasulikkus sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Depending on the condition it is used to treat, Blitzima may be given with chemotherapy (other cancer medicines) or medicines used for inflammatory disorders (corticosteroids).
Estonian: Sõltuvalt ravitavast seisundist võib Blitzimat manustada koos keemiaravi (muud vähiravimid) või põletikuvastaste ravimitega (kortikosteroidid).
English: Doctors prescribing Blitzima for cancer will be provided with educational material reminding them of the need to use the medicine only by infusion into a vein.
Estonian: Blitzimat vähiraviks määravatele arstidele antakse teabematerjal, milles neile tuletatakse meelde, et ravimit manustatakse üksnes veeniinfusiooniga.
English: Patients with GPA or MPA must also not receive Blitzima if they have severe heart problems.
Estonian: Granulomatoosse polüangiidi või mikroskoopilise polüangiidiga patsiendid ei tohi kasutada Blitzimat raskete südameprobleemide korral.
English: The study showed that Blitzima and MabThera had comparable effects on arthritis symptoms: after 24 weeks, the proportion of patients with a 20% improvement in symptom score (called ACR20) was 74% (114 of 155 patients) with Blitzima and 73% (43 of 59 patients) with MabThera.
Estonian: Uuringu kohaselt oli neil kahel ravimil artriidisümptomitele võrreldav toime: 24 nädala järel saavutas ACR20-skoori järgi 20% paranemise 74% Blitzimat kasutanud patsientidest (114 patsienti 155st) ja 73% MabTherat kasutanud patsientidest (43 patsienti 59st).
English: Blitzima should be given under the close supervision of an experienced healthcare professional and in a place where facilities for resuscitating patients are immediately available.
Estonian: Blitzimat tohib manustada üksnes kogenud tervishoiutöötaja järelevalve all ja patsientide kohese elustamisvõimalusega haiglakeskkonnas.
English: Because Blitzima is a biosimilar medicine, the studies on effectiveness and safety of rituximab carried out with MabThera do not all need to be repeated for Blitzima.
Estonian: Et Blitzima on bioloogiliselt sarnane ravim, ei pea MabTheraga tehtud rituksimabi efektiivsus- ja ohutusuuringuid Blitzimaga kordama.
English: In addition, a study comparing Blitzima to MabThera in patients with rheumatoid arthritis (which can support its use in other inflammatory disorders such as GPA and MPA) showed that both medicines are similarly effective, and a supportive study in follicular lymphoma showed effectiveness in cancer.
Estonian: Peale selle näitas uuring, milles võrreldi Blitzimat MabTheraga reumatoidartriidiga patsientidel (ja mis võib toetada ravimi kasutamist muude põletikuhaiguste, nagu granulomatoosse polüangiidi ja mikroskoopilise polüangiidi ravis), nende ravimite võrreldavat efektiivsust ning toetav uuring follikulaarse lümfoomiga patsientidel tõendas efektiivsust vähiravis.
English: For practical information about using Blitzima, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Blitzima kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Blitzima rituximab
Estonian: Blitzima rituksimab
English: • follicular lymphoma and diffuse large B cell non-Hodgkin's lymphoma (two types of non-Hodgkin's lymphoma, a blood cancer);
Estonian: • follikulaarne lümfoom ja difuusne B-suurerakuline mitte-Hodgkini lümfoom (mitte-Hodgkini lümfoomi, teatud verevähi kaks tüüpi);
English: Blitzima must not be used in people who are hypersensitive (allergic) to rituximab, mouse proteins or any of the other ingredients.
Estonian: Blitzimat ei tohi kasutada patsiendid, kes on rituksimabi, hiirevalkude või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For more information about treatment with Blitzima, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Blitzimaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Thus, all these data were considered sufficient to conclude that Blitzima will behave in the same way in terms of effectiveness as MabThera in its approved indications.
Estonian: Nende piisavate andmete põhjal järeldati, et Blitzima efektiivsus on heakskiidetud näidustustel võrreldav MabThera efektiivsusega.
English: Studies have also shown that giving Blitzima produces similar levels of the active substance in the body to giving MabThera.
Estonian: Uuringud on samuti näidanud, et Blitzima põhjustab organismis samasuguse toimeainesisalduse kui MabThera.
English: For the full list of side effects reported with Blitzima, see the package leaflet.
Estonian: Blitzima kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Blitzima used?
Estonian: Kuidas Blitzimat kasutatakse?
English: In addition, Blitzima has been compared with MabThera given into a vein in a main study involving 372 patients with active rheumatoid arthritis (an inflammatory disease).
Estonian: Lisaks võrreldi Blitzimat MabTheraga põhiuuringus, milles 372 aktiivse reumatoidartriidiga (põletikuhaigus) patsiendile manustati neid ravimeid veeni.
English: The company that markets Blitzima will provide doctors and patients using the medicine for non-cancer conditions with educational material including information on the need to give the medicine where facilities for resuscitation are available and on the risk of infection, including PML.
Estonian: Blitzima turustaja annab ravimit muude haiguste kui vähi raviks kasutavatele arstidele ja patsientidele teabematerjalid, milles rõhutatakse vajadust manustada ravimit tingimustes, kus on olemas elustamisvahendid, ning teavitatakse neid infektsioonide, sh progresseeruva multifokaalse leukoentsefalopaatia riskist.
English: The active substance in Blitzima, rituximab, is a monoclonal antibody (a type of protein) designed to recognise and attach to a protein called CD20 present on the surface of B cells (types of white blood cells).
Estonian: Blitzima toimeaine rituksimab on monoklonaalne antikeha (teatud valk), mis tunneb ära Blümfotsüütide (teatud valgeliblede) pinnal oleva valgu CD20 ja seondub sellega.
English: • granulomatosis with polyangiitis (GPA or Wegener's granulomatosis) and microscopic polyangiitis (MPA), which are inflammatory conditions of the blood vessels.
Estonian: • granulomatoosne polüangiit (GPA ehk Wegeneri granulomatoos) ja mikroskoopiline polüangiit
English: How does Blitzima work?
Estonian: Kuidas Blitzima toimib?
English: Blitzima contains the active substance rituximab.
Estonian: Blitzima sisaldab toimeainena rituksimabi.
English: The reference medicine for Blitzima is MabThera.
Estonian: Blitzima võrdlusravim on MabThera.